Vaccines against poverty

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12307-12312

  MacLennan, Calman A ^a,b   Saul, Allan ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; VACCINE; BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE;

AFRICAN; BASIC RESEARCH; DIARRHEA; HEALTH CARE PERSONNEL; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MENINGITIS; PNEUMOCOCCAL INFECTION; POVERTY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; ROTAVIRUS INFECTION; SEPSIS; STREPTOCOCCUS GROUP A; TUBERCULOSIS; VACCINATION; DEVELOPING COUNTRY; ECONOMICS; HEALTH; HUMAN; INFECTION CONTROL; NEGLECTED DISEASES; PROCEDURES; RESPIRATORY TRACT INFECTIONS;

AIDS VACCINES; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; DIARRHEA; GLOBAL HEALTH; HUMANS; MALARIA VACCINES; NEGLECTED DISEASES; POVERTY AREAS; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS VACCINES; VACCINES;

EID: 84906693627     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400473111     Document Type: Review

References (48)

1. Plotkin SA (2009) Vaccines: The fourth century. Clin Vaccine Immunol 16(12):1709-1719.
2. Bloom DE, Canning D, Weston M (2005) The value of vaccination. World Econ 6(3):15-39.
3. Centers for Disease Control and Prevention (CDC) (2010) Global routine vaccination coverage, 2009. MMWR Morb Mortal Wkly Rep 59(42):1367-1371.
4. GAVI Alliance (2014) Saving children's lives and protecting people's health by increasing access to immunisation in poor countries. Available at http://www.gavialliance.org/. Accessed February 12, 2014.
5. United Nations Development Programme (2014) The Millenium development goals. Available at http://www.undp.org/content/undp/en/home/mdgoverview/. Accessed February 12, 2014.
6. World Health Organization (2011) Mr Bill Gates, Co-chair of the Bill & Melinda Gates Foundation Speech to the sixty-fourth World Health Assembly. Available at http://www.who.int/mediacentre/events/2011/wha64/bill-gates- speech-20110517/en/index.html. Accessed February 12, 2014.
7. World Health Organization (2013) Global vaccine action plan 2011-2020. Available at http://www.dovcollaboration.org/wpcontent/uploads/2013/03/ GlobalVaccineActionPlan-interactive.pdf. Accessed March 29, 2014.
8. Institute for Health Metrics and Evaluation (2010) Global burden of diseases, injuries, and risk factors study 2010. Available at http://www.healthmetricsandevaluation.org/gbd/research/project/ global-burden-diseases-injuries-and-risk-factors-study-2010. Accessed February 12, 2014.
9. Lozano R, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095-2128.
10. Murray CJ, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2197-2223.
11. Wang H, et al. (2012) Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2071-2094.
12. PATH (2014) Malaria vaccine initiative. Available at http://www. malariavaccine.org/. Accessed February 12, 2014.
13. Global HIV Vaccine Enterprise (2014) Global HIV Vaccine Enterprise. Available at http://www.vaccineenterprise.org/. Accessed February 12, 2014.
14. AERAS. (2014) AERAS advancing tuberculosis vaccines for the world. Available at http://www.aeras.org. Accessed February 12, 2014.
15. Agnandji ST, et al.; RTS,S Clinical Trials Partnership (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365(20):1863-1875.
16. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
17. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640.
18. McShane H (2011) Tuberculosis vaccines: Beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 366(1579): 2782-2789.
19. Hotez PJ, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357(10):1018-1027. (Pubitemid 47367081)
20. World Health Organization (2012) Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. Available at http://www.who.int/neglected-diseases/NTD-RoadMap-2012-Fullversion.pdf. Accessed February 12, 2014.
21. Uniting to Combat NTDs (2012) The London declaration on neglected tropical diseases. Available at http://www.unitingtocombatntds.org/downloads/ press/london-declaration-on-ntds.pdf. Accessed February 12, 2014.
22. World Health Organization (2013) Sustaining the drive to overcome the global impact of neglected tropical diseases. Available at www.who.int/iris/ bitstream/10665/77950/1/9789241564540-eng.pdf. Accessed February 12, 2014.
23. Berkley JA, et al. (2005) Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352(1):39-47. (Pubitemid 40075679)
24. Deen J, et al. (2012) Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: A systematic review. Lancet Infect Dis 12(6):480-487.
25. Reddy EA, Shaw AV, Crump JA (2010) Community-acquired bloodstream infections in Africa: A systematic review and meta-analysis. Lancet Infect Dis 10(6):417-432.
26. MacLennan CA, Levine MM (2013) Invasive nontyphoidal Salmonella disease in Africa: current status. Expert Rev Anti Infect Ther 11(5):443-446.
27. Martin LB (2012) Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis 25(5):489-499.
28. Bhutta ZA, et al. (2014) Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: Results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis 14(2):119-129.
29. Douglas RG, Sadoff J, Samant V (2008) The vaccine industry. Vaccines, eds Plotkin SA, Orenstein WA, Offit PA (Saunders Elsevier, Philadelphia), pp 37-44.
30. Moxon ER, et al. (2011) A call to action for the new decade of vaccines. Lancet 378(9788):298-302.
31. Gordon SB, et al. (2003) Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi. Emerg Infect Dis 9(6):747-749. (Pubitemid 36676376)
32. Holmgren J, Svennerholm AM (2012) Vaccines against mucosal infections. Curr Opin Immunol 24(3):343-353.
33. Policy Cures G-FINDER (2013) Neglected disease research and development: The public divide. Available at http://www.policycures.org/downloads/GF- report13-all-web.pdf. Accessed February 12, 2014.
34. Anker M (1997) The effect of misclassification error on reported cause-specific mortality fractions from verbal autopsy. Int J Epidemiol 26(5):1090-1096.
35. Lozano R, et al.; Population Health Metrics Research Consortium (PHMRC) (2011) Performance of physician-certified verbal autopsies: Multisite validation study using clinical diagnostic gold standards. Popul Health Metr 9:32.
36. Liu L, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF (2012) Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 379(9832):2151-2161.
37. Kotloff KL, et al. (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. Lancet 382(9888):209-222.
38. Levine OS, et al. (2012) The Pneumonia Etiology Research for Child Health Project: A 21st century childhood pneumonia etiology study. Clin Infect Dis 54(Suppl 2):S93-101.
39. Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25(12):1361-1366.
40. Levine OS, et al. (2011) The future of immunisation policy, implementation, and financing. Lancet 378(9789):439-448.
41. Plosker GL (2011) Rotavirus vaccine RIX4414 (Rotarix™): A pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 29(5):439-454.
42. Hargreaves JR, et al. (2011) Making new vaccines affordable: A comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Lancet 378(9806):1885-1893.
43. Sow SO, et al. (2011) Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 364(24):2293-2304.
44. Pagliusi S, et al. (2013) Developing countries vaccine manufacturers network: Doing good by making high-quality vaccines affordable for all. Vaccine 31(Suppl 2):B176-B183.
45. MacLennan CA (2013) Vaccines for low-income countries. Semin Immunol 25(2):114-123.
46. Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9(3):213-220.
47. Berlanda Scorza F, et al. (2012) High yield production process for Shigella outer membrane particles. PLoS ONE 7(6):e35616.
48. Koeberling O, et al. (2014) A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine 32(23):2688-2695.